Personal information

Other IDs

Scopus Author ID: 43561336800

Countries

United States

Activities

Collapse all

Employment (1)

Memorial Sloan Kettering Cancer Center: New York, US

2014-07 to present
Employment
Source: check_circle
Memorial Sloan Kettering Cancer Center

Works (44)

HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML

Leukemia & Lymphoma
2025-01-28 | Journal article
DOI: 10.1080/10428194.2024.2411436
Contributors: Kuo-Kai Chin; Andriy Derkach; Christopher Famulare; Gaurav K. Gupta; P. Dayand Borge; Mark B. Geyer; Aaron D. Goldberg; Tamanna Haque; Jae H. Park; Lindsey E. Roeker et al.
Source: check_circle
Crossref

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia

Blood Neoplasia
2024-12 | Journal article
DOI: 10.1016/j.bneo.2024.100038
Contributors: Kuo-Kai Chin; Yannis Valtis; Andriy Derkach; Meira Yisraeli Salman; Leora Boussi; Jenna Ciervo; Mark B. Geyer; Jae H. Park; Martin S. Tallman; Jacob L. Glass et al.
Source: check_circle
Crossref

Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax

Blood Advances
2024-11-26 | Journal article
DOI: 10.1182/bloodadvances.2024013927
Contributors: Yannis K. Valtis; David Nemirovsky; Andriy Derkach; Saumya Sharan; Charlene Kabel; Ricardo Ortiz; Meghan C. Thompson; Lindsey E. Roeker; Mark B. Geyer
Source: check_circle
Crossref

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

Leukemia & Lymphoma
2023-07-29 | Journal article
DOI: 10.1080/10428194.2023.2221756
Contributors: Rose Parisi; Emily A. Cowen; Stephanie Gu; Stephen Dusza; Melissa Pulitzer; Mark B. Geyer; Amber C. King; Alina Markova
Source: check_circle
Crossref

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal

Blood Advances
2023-07-11 | Journal article
DOI: 10.1182/bloodadvances.2022009212
Contributors: Mark B. Geyer; Brian C. Shaffer; Bhavana Bhatnagar; Alice S. Mims; Victoria Klein; Deepika Dilip; Jacob L. Glass; Gerard Lozanski; Hani Hassoun; Heather Landau et al.
Source: check_circle
Crossref

Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

2023-04-04 | Preprint
DOI: 10.1158/2326-6066.c.6549864.v1
Contributors: Eric L. Smith; Sham Mailankody; Mette Staehr; Xiuyan Wang; Brigitte Senechal; Terence J. Purdon; Anthony F. Daniyan; Mark B. Geyer; Aaron D. Goldberg; Elena Mead et al.
Source: check_circle
Crossref

Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

2023-04-04 | Preprint
DOI: 10.1158/2326-6066.c.6549864
Contributors: Eric L. Smith; Sham Mailankody; Mette Staehr; Xiuyan Wang; Brigitte Senechal; Terence J. Purdon; Anthony F. Daniyan; Mark B. Geyer; Aaron D. Goldberg; Elena Mead et al.
Source: check_circle
Crossref

Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

2023-04-04 | Preprint
DOI: 10.1158/2326-6066.22542300
Contributors: Eric L. Smith; Sham Mailankody; Mette Staehr; Xiuyan Wang; Brigitte Senechal; Terence J. Purdon; Anthony F. Daniyan; Mark B. Geyer; Aaron D. Goldberg; Elena Mead et al.
Source: check_circle
Crossref

Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

2023-04-04 | Preprint
DOI: 10.1158/2326-6066.22542300.v1
Contributors: Eric L. Smith; Sham Mailankody; Mette Staehr; Xiuyan Wang; Brigitte Senechal; Terence J. Purdon; Anthony F. Daniyan; Mark B. Geyer; Aaron D. Goldberg; Elena Mead et al.
Source: check_circle
Crossref

Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab

Blood Advances
2022-03-08 | Journal article
DOI: 10.1182/bloodadvances.2021005978
Contributors: Kitsada Wudhikarn; Amber C. King; Mark B. Geyer; Mikhail Roshal; Yvette Bernal; Boglarka Gyurkocza; Miguel-Angel Perales; Jae H. Park
Source: check_circle
Crossref

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Blood
2021-08-19 | Journal article
DOI: 10.1182/blood.2020009515
Contributors: Kitsada Wudhikarn; Jessica R. Flynn; Isabelle Rivière; Mithat Gönen; Xiuyan Wang; Brigitte Senechal; Kevin J. Curran; Mikhail Roshal; Peter G. Maslak; Mark B. Geyer et al.
Source: check_circle
Crossref

Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality

Leukemia & Lymphoma
2021-07-03 | Journal article
DOI: 10.1080/10428194.2021.1885664
Contributors: Maximilian Stahl; Varun Narendra; Justin Jee; Andriy Derkach; Molly Maloy; Mark B. Geyer; Anthony R. Mato; Lindsey E. Roeker; Martin S. Tallman; Gunjan L. Shah et al.
Source: check_circle
Crossref

Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia

Leukemia & Lymphoma
2021-01-02 | Journal article
DOI: 10.1080/10428194.2020.1824068
Contributors: Ryan J. Daley; Sridevi Rajeeve; Charlene C. Kabel; Jeremy J. Pappacena; Sarah E. Stump; Jessica A. Lavery; Martin S. Tallman; Mark B. Geyer; Jae H. Park
Source: check_circle
Crossref

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia.

Haematologica
2020-10-13 | Journal article
DOI: 10.3324/haematol.2020.251686
PMID: 33054114
Source: Self-asserted source
Mark B. Geyer

Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naïve acute lymphoblastic leukemia

Leukemia & Lymphoma
2020-08-23 | Journal article
DOI: 10.1080/10428194.2020.1765236
Contributors: Charles Gaulin; Angela Chan; Andriy Derkach; Jae H. Park; Simon Mantha; Mark B. Geyer; Martin S. Tallman
Source: check_circle
Crossref

Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features

Leukemia Research Reports
2019-11 | Journal article
DOI: 10.1016/j.lrr.2019.100186
Contributors: Xiaochuan Yang; Filiz Sen; Mark B. Geyer
Source: check_circle
Crossref

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Cancer Immunology Research
2019-07-01 | Journal article
DOI: 10.1158/2326-6066.CIR-18-0551
Contributors: Eric L. Smith; Sham Mailankody; Mette Staehr; Xiuyan Wang; Brigitte Senechal; Terence J. Purdon; Anthony F. Daniyan; Mark B. Geyer; Aaron D. Goldberg; Elena Mead et al.
Source: check_circle
Crossref

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL

JCI Insight
2019-05-02 | Journal article
DOI: 10.1172/jci.insight.122627
Contributors: Mark B. Geyer; Isabelle Rivière; Brigitte Sénéchal; Xiuyan Wang; Yongzeng Wang; Terence J. Purdon; Meier Hsu; Sean M. Devlin; M. Lia Palomba; Elizabeth Halton et al.
Source: check_circle
Crossref

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Leukemia Research
2019-04 | Journal article
DOI: 10.1016/j.leukres.2019.02.009
Contributors: Amber C. King; Jeremy J. Pappacena; Martin S. Tallman; Jae H. Park; Mark B. Geyer
Source: check_circle
Crossref

BRAF in the cross-hairs

Expert Review of Hematology
2019-03-04 | Journal article
DOI: 10.1080/17474086.2019.1583553
Contributors: Mark B. Geyer; Omar Abdel-Wahab; Martin S. Tallman
Source: check_circle
Crossref

First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval

Clinical Cancer Research
2019-02-15 | Journal article
DOI: 10.1158/1078-0432.CCR-18-3328
Contributors: Mark B. Geyer
Source: check_circle
Crossref

The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia

Bone Marrow Transplantation
2019-02-13 | Journal article
DOI: 10.1038/s41409-018-0247-9
Contributors: Jessica Hochberg; Stacey Zahler; Mark B. Geyer; Nan Chen; Jennifer Krajewski; Lauren Harrison; Olga Militano; M. Fevzi Ozkaynak; Alexandra C. Cheerva; Julie Talano et al.
Source: check_circle
Crossref

Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells

Leukemia & Lymphoma
2018-07-03 | Journal article
DOI: 10.1080/10428194.2017.1390237
Contributors: Mark B. Geyer; Shwetha H. Manjunath; Andrew G. Evans; Jae H. Park; Marco L. Davila; Corey S. Cutler; Xiuyan Wang; Yongzeng Wang; Brigitte Senechal; Isabelle Rivière et al.
Source: check_circle
Crossref

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.

Molecular therapy : the journal of the American Society of Gene Therapy
2018-06-15 | Journal article
DOI: 10.1016/j.ymthe.2018.05.018
PMID: 29910179
PMC: PMC6094824
Source: Self-asserted source
Mark B. Geyer

Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission

Leukemia & Lymphoma
2018-02-28 | Journal article
DOI: 10.1080/10428194.2017.1355971
Contributors: Mark B. Geyer; Martin S. Tallman
Source: check_circle
Crossref

Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis

Blood
2017-03-30 | Journal article
DOI: 10.1182/blood-2016-11-749507
Contributors: Mark B. Geyer; Meier Hsu; Sean M. Devlin; Martin S. Tallman; Dan Douer; Jae H. Park
Source: check_circle
Crossref

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date

Blood
2016 | Journal article
DOI: 10.1182/blood-2016-02-629063
EID:

2-s2.0-84977489592
Contributors: Park, J.H.; Geyer, M.B.; Brentjens, R.J.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier
grade
Preferred source (of 2)‎

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells

Cytotherapy
2016 | Journal article
DOI: 10.1016/j.jcyt.2016.07.003
EID:

2-s2.0-84992655487
Contributors: Geyer, M.B.; Brentjens, R.J.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa

The Journal of Pediatrics
2015-09 | Journal article
DOI: 10.1016/j.jpeds.2015.05.051
Contributors: Mark B. Geyer; Kavita Radhakrishnan; Roger Giller; Noriko Umegaki; Sivan Harel; Maija Kiuru; Kimberly D. Morel; Nicole LeBoeuf; Jessica Kandel; Anna Bruckner et al.
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

A Comparison of Bronchoalveolar Lavage versus Lung Biopsy in Pediatric Recipients after Stem Cell Transplantation

Biology of Blood and Marrow Transplantation
2014 | Journal article
DOI: 10.1016/j.bbmt.2014.04.019
EID:

2-s2.0-84904046598
Contributors: Qualter, E.; Satwani, P.; Ricci, A.; Jin, Z.; Geyer, M.B.; Alobeid, B.; Radhakrishnan, K.; Bye, M.; Middlesworth, W.; Della-Letta, P. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Enhanced survival during experimental Listeria monocytogenes sepsis in neonatal mice prophylactically treated with Th1 and macrophage immunoregulatory cytokines and mediators

Pediatric Infectious Disease Journal
2014 | Journal article
DOI: 10.1097/INF.0000000000000442
EID:

2-s2.0-84926206101
Contributors: Geyer, M.B.; Radhakrishnan, K.; Van De Ven, C.; Suri, M.S.; Ayello, J.; Cairo, M.S.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Pilot trial of risk-adapted cyclophosphamide intensity based conditioning and HLA matched sibling and unrelated cord blood stem cell transplantation in newly diagnosed pediatric and adolescent recipients with acquired severe aplastic anemia

Pediatric Blood and Cancer
2014 | Journal article
DOI: 10.1002/pbc.24976
EID:

2-s2.0-84899694796
Contributors: Mcguinn, C.; Geyer, M.B.; Jin, Z.; Garvin, J.H.; Satwani, P.; Bradley, M.B.; Bhatia, M.; George, D.; Duffy, D.; Morris, E. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease

Bone Marrow Transplantation
2014 | Journal article
DOI: 10.1038/bmt.2014.84
EID:

2-s2.0-84903882984
Contributors: Bhatia, M.; Jin, Z.; Baker, C.; Geyer, M.B.; Radhakrishnan, K.; Morris, E.; Satwani, P.; George, D.; Garvin, J.; Del Toro, G. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Busulfan, Fludarabine, and Alemtuzumab Conditioning and Unrelated Cord Blood Transplantation in Children with Sickle Cell Disease

Biology of Blood and Marrow Transplantation
2013 | Journal article
DOI: 10.1016/j.bbmt.2013.02.002
EID:

2-s2.0-84875536038
Contributors: Radhakrishnan, K.; Bhatia, M.; Geyer, M.B.; del Toro, G.; Jin, Z.; Baker, C.; Harrison, L.; Morris, E.; Baxter-Lowe, L.A.; Cairo, M.S.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: A Children's Oncology Group report

Leukemia
2013 | Journal article
DOI: 10.1038/leu.2012.255
EID:

2-s2.0-84877619828
Contributors: Goldman, S.; Smith, L.; Anderson, J.R.; Perkins, S.; Harrison, L.; Geyer, M.B.; Gross, T.G.; Weinstein, H.; Bergeron, S.; Shiramizu, B. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report

British Journal of Haematology
2013 | Journal article
DOI: 10.1111/bjh.12434
EID:

2-s2.0-84881663487
Contributors: Barth, M.J.; Goldman, S.; Smith, L.; Perkins, S.; Shiramizu, B.; Gross, T.G.; Harrison, L.; Sanger, W.; Geyer, M.B.; Giulino-Roth, L. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients

Bone Marrow Transplantation
2013 | Journal article
DOI: 10.1038/bmt.2012.105
EID:

2-s2.0-84872149353
Contributors: Le Gall, J.B.; Milone, M.C.; Waxman, I.M.; Shaw, L.M.; Harrison, L.; Duffy, D.; Van De Ven, C.; Militano, O.; Geyer, M.B.; Morris, E. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Adenovirus infection in paediatric allogeneic stem cell transplantation recipients is a major independent factor for significantly increasing the risk of treatment related mortality

British Journal of Haematology
2012 | Journal article
DOI: 10.1111/j.1365-2141.2010.08468.x
EID:

2-s2.0-83555166294
Contributors: George, D.; El-Mallawany, N.K.; Jin, Z.; Geyer, M.; Della-Latta, P.; Satwani, P.; Garvin, J.H.; Bradley, M.B.; Bhatia, M.; van de Ven, C. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Epidemiology of hematological malignancies of children, adolescents, and young adults

Hematological Malignancies: In Children, Adolescents and Young Adults
2012 | Book
DOI: 10.1142/9789814299619_0001
EID:

2-s2.0-84973140734
Contributors: Geyer, M.B.; Jacobson, J.S.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Starry sky

British Journal of Haematology
2012 | Journal article
DOI: 10.1111/j.1365-2141.2012.09036.x
EID:

2-s2.0-84857785701
Contributors: Geyer, M.B.; Cairo, M.S.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

T cell depletion utilizing CD34 + stem cell selection and CD3 + addback from unrelated adult donors in paediatric allogeneic stem cell transplantation recipients

British Journal of Haematology
2012 | Journal article
DOI: 10.1111/j.1365-2141.2012.09048.x
EID:

2-s2.0-84859215762
Contributors: Geyer, M.B.; Ricci, A.M.; Jacobson, J.S.; Majzner, R.; Duffy, D.; Van de Ven, C.; Ayello, J.; Bhatia, M.; Garvin, J.H.; George, D. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients

British Journal of Haematology
2011 | Journal article
DOI: 10.1111/j.1365-2141.2011.08822.x
EID:

2-s2.0-80053560138
Contributors: Geyer, M.B.; Jacobson, J.S.; Freedman, J.; George, D.; Moore, V.; Van De Ven, C.; Satwani, P.; Bhatia, M.; Garvin, J.H.; Bradley, M.B. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

Cord blood transplantation and stem cell regenerative potential

Experimental Hematology
2011 | Journal article
DOI: 10.1016/j.exphem.2011.01.002
EID:

2-s2.0-79952639189
Contributors: Liao, Y.; Geyer, M.B.; Yang, A.J.; Cairo, M.S.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier

IgH class switching and translocations use a robust non-classical end-joining pathway

Nature
2007 | Journal article
DOI: 10.1038/nature06020
EID:

2-s2.0-34748863465
Contributors: Yan, C.T.; Boboila, C.; Souza, E.K.; Franco, S.; Hickernell, T.R.; Murphy, M.; Gumaste, S.; Geyer, M.; Zarrin, A.A.; Manis, J.P. et al.
Source: Self-asserted source
Mark B. Geyer via Scopus - Elsevier
How many people are using ORCID?